Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05902819
Other study ID # 2022-01177
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 10, 2023
Est. completion date December 31, 2024

Study information

Verified date December 2023
Source Psychiatric University Hospital, Zurich
Contact Amelie Zacher, MSc.
Phone +41 58 384 35 54
Email ameliesophie.zacher@bli.uzh.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An investigation of the effect of matrix-metalloproteinase-(MMP)-9 inhibition with minocycline on the reconsolidation of trauma- or cocaine-related memories


Description:

Intrusive memories are involuntary recollections of past emotional events that can become pathological and persist over time, particularly in post-traumatic stress disorder (PTSD) and cocaine use disorders (CUD). Both PTSD and CUD are characterised by a hypersensitivity and -reactivity to cue-elicited memory reactivation and exhibit common neurological alterations, suggesting shared underlying mechanisms. As intrusive memories significantly contribute to maintaining the cycle of relapse in both disorders, it is important to find a way to attenuate them successfully. Research on memory reconsolidation has led to the development of different (pharmacological) approaches to disrupt the process, which have, however, yielded mixed and unspecific effects so far. The present project aims to investigate the effect of MMP-9 inhibition with minocycline on the reconsolidation of intrusive memories in individuals with CUD or PTSD. Participants will be randomly assigned to a minocycline or placebo group. The study comprises a total of 5 visits during 3 weeks and one follow-up online survey (3 months after the intervention). Participants will receive the study medication before two imagery script-guided memory activation sessions. An ecological momentary assessment (EMA) approach will be employed to track intrusive memories, and glutamate concentration and neural activation will be measured with magnetic resonance spectroscopy (MRS) and functional magnetic resonance (fMRI), respectively, before and after the two imagery sessions.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date December 31, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility General Inclusion Criteria: - Ability to read, understand and provide written informed consent - Age between 18 and 60 years - To be sufficiently fluent in German Inclusion Criteria for the PTSD group: - Current diagnosis of full PTSD according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), of subthreshold PTSD, as in meeting two to three of the DSM-5 criteria B-E, or of complex PTSD Inclusion Criteria for the CUD group: - Current diagnosis of mild, moderate, or severe CUD according to DSM-5 - Regular cocaine use in the last 12 months and at least one consumption event in the last 6 months Inclusion Criteria for the Clinical Controls (PTSD+CUD group): - Current diagnosis of full PTSD according to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), of subthreshold PTSD, as in meeting two to three of the DSM-5 criteria B-E, or of complex PTSD - Current diagnosis of mild, moderate, or severe CUD according to DSM-5 - Regular cocaine use in the last 12 months and at least one consumption event in the last 6 months General Exclusion Criteria: - Women who are pregnant or breast feeding or intending to become pregnant during the course of the study or within 3 months after - Other clinically significant concomitant disease states, e.g., renal failure (i.e., estimated glomerular filtration rate (eGFR; CKD-EPI) lower than 60 ml/min/1.73 m2), hepatic dysfunction (i.e., alanine transaminase (ALT) higher than 90 U/I for women or 110 U/I for men, aspartate aminotransferase (AST) higher than 74 U/I, and/or gamma-glutamyl transferase (?GT) higher than 70 U/I for women or 120 U/I for men), cardiovascular disease, etc. - Presence or history of severe neurological disorders, head injuries or systemic/rheumatic disease - Diagnosis of schizophrenia, bipolar disorder, or autism spectrum disorder according to DSM-5 - Pacemaker, neurostimulator or any other head or heart implants as well as MRI-incompatible metal parts or possibility of metal fragments in the body (MR safety) - Claustrophobia (MR safety) - Dependence on a hearing aid (MR safety) - Inability to follow the procedures of the study, e.g., due to language problems - Participation in another study with investigational drugs within the 30 days preceding and during the present study - More than three suicide attempts in the past, a suicide attempt within the last 12 months and/or acute suicidality Exclusion Criteria for Healthy Controls: - Any current psychiatric diagnosis according to DSM-5 except for mild or moderate substance use disorder (SUD) for nicotine, and mild SUD for alcohol and cannabis - Diagnosis of CUD according to DSM-5 (lifetime) - Diagnosis of PTSD according to DSM-5 (lifetime) Exclusion Criteria for both the PTSD and CUD groups: - Allergy to minocycline or to any other ingredient in the named drug - Current intake of the following medications interacting with minocycline: acitretin, acetylcystein, aluminiumhydroxid, amitryptiline, any antibiotics, antidiabetic drug such as sulfonylurea, atazanavir, atomoxetine, anticoagulant drugs from the coumarin type, barbiturates, bupropion, carbamazepine, ciclosporin A, isotretinoin, methotrexate, phenytoin, and theophylline Exclusion Criteria for only the PTSD group: - Diagnosis of CUD according to DSM-5 (lifetime) - Current diagnosis of severe SUD for nicotine, moderate SUD for alcohol and cannabis, and mild SUD for all other substances according to DSM-5 Exclusion Criteria for only the CUD group: - Diagnosis of PTSD according to DSM-5 (lifetime) - Current diagnosis of severe SUD for alcohol or cannabis, and mild SUD for all other substances (except for nicotine) according to DSM-5 Exclusion Criteria for Clinical Controls (PTSD+CUD group): - Current diagnosis of severe SUD for alcohol or cannabis, and mild SUD for all other substances (except for nicotine) according to DSM-5

Study Design


Intervention

Behavioral:
Imagery
Guided imagery of personal trauma- or cocaine-related memory approximately 120min after study medication was given.
Drug:
Minocycline
Single dose of minocycline (200mg) at each of two imagery sessions; Minocycline is given orally in form of a capsule.
Placebo
Single dose of mannitol (100%) at each of two imagery sessions; Placebo is given orally in form of a capsule.

Locations

Country Name City State
Switzerland Psychiatric University Hospital Zurich, University of Zurich Zürich

Sponsors (2)

Lead Sponsor Collaborator
Psychiatric University Hospital, Zurich University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in intrusive memories frequency and features Measured with the Intrusion Questionnaire, containing various items on intrusive memories frequency, arousal and distress as well as triggers, and responses. Changes from baseline intrusive memories frequency and features after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2)
Primary Change over time in self-reported intrusive memories frequency, arousal and distress Captured with a short version of the Intrusion Questionnaire implemented as smartphone-based ecological momentary assessment (EMA), containing items on arousal and distress from self-reported intrusive memories. EMA will be conducted for an average of 12 to 42 days (through study participation from baseline to 3 days after follow-up 1).
Primary Changes in fMRI Blood-Oxygenation-Level Dependent (BOLD) contrasts fMRI BOLD contrasts between conditions (neutral/stress/trauma for the PTSD group; neutral/reward/drug for the CUD group) and between groups. Changes from baseline fMRI BOLD contrasts after 9 to max. 39 days (follow-up 1).
Primary Changes in MRS signal parameters Glutamate concentrations are measured using MRS in the amygdala in the PTSD group and in the nucleus accumbens in the CUD group. Change from baseline MRS-measured glutamate concentrations after 9 to max. 39 days (follow-up 1).
Secondary Change in heart rate variability (HRV) during fMRI memory reactivation HRV will be measured during the fMRI cue-reactivity paradigm (listening to trauma- or cocaine-related narratives compared to trauma- and cocaine-unrelated narratives). Change from baseline HRV after 9 to max. 39 days (follow-up 1).
Secondary Change in respiratory rate during fMRI memory reactivation Respiratory rate will be measured during the fMRI cue-reactivity paradigm (listening to trauma- or cocaine-related narratives compared to trauma- and cocaine-unrelated narratives). Change from baseline respiratory rate after 9 to max. 39 days (follow-up 1).
Secondary Change in subjective rating of distress before and after memory reactivation Current subjective distress will be measured with a visual analogue scale before and after listening to trauma- and cocaine-related narratives compared to trauma- and cocaine-unrelated narratives. Change from baseline subjective distress after 9 to max. 39 days (follow-up 1).
Secondary Change in subjective rating of craving before and after memory reactivation Current subjective craving will be measured with the Cocaine Craving Questionnaire (containing ten questions on current craving scaled from 0 to 10) before and after listening to cocaine-related narratives compared to cocaine-unrelated narratives. Change from baseline craving after 9 to max. 39 days (follow-up 1).
Secondary Change in neurofilament light chain (NfL) levels NfL levels will be measured in serum samples. Change from baseline NfL levels after 9 to max. 39 days (follow-up 1).
Secondary Change in sphingolipid levels Sphingolipid levels will be measured in plasma samples. Change from baseline sphingolipid levels after 9 to max. 39 days (follow-up 1).
Secondary Change in inflammatory biomarker levels Inflammatory biomarker levels will be measured in serum samples. Change from baseline inflammatory levels after 9 to max. 39 days (follow-up 1).
Secondary Change in MMP-9 protein levels MMP-9 protein levels will be measured in plasma samples. Change from baseline MMP-9 protein levels after 9 to max. 39 days (follow-up 1).
Secondary Change in MMP-9 gene expression MMP-9 gene expression will be measured in blood samples. Change from baseline MMP-9 gene expression after 9 to max. 39 days (follow-up 1).
Secondary Heartrate variability Heartrate variability (measured with a wearable (Fitbit)) predicted by the number and quality of intrusive memories experienced. Overall variability per person, in relation to overall health measured at Screening and Baseline as well as pre- and post-intervention variability will be assessed. Will be measured during 9 to max. 39 days, from baseline until follow-up 1.
Secondary Sleep duration Sleep duration (in minutes), trajectories over the course of the study periods, clusters of variations in duration and sleep quality (as averaged by the algorithm of Fitbit), according to medication/placebo, number of intrusions and overall health measured at Screening and Baseline. Will be measured during 9 to max. 39 days, from baseline until follow-up 1.
Secondary Change in Obsessive Compulsive Cocaine Use Scale (OCCUS) A 14-item self-report measure that assesses the current inability to control or resist cocaine-related thoughts and behaviors, frequency and impact of thoughts and impulses related to cocaine use, and the degree of interference caused by cocaine related thoughts and behaviors. Change from baseline OCCUS score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
Secondary PTSD Checklist for DSM-5 (PCL-5) A 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD in the last 2 weeks prior to the visit. Change from baseline PCL-5 score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
Secondary Beck Depression Inventory-II (BDI-II) A 21-item self-report measure for assessing the severity of depression in the last 2 weeks prior to the visit. Change from baseline BDI-II score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
Secondary Pittsburgh Sleep Quality Index (PSQI) A 19-item self-report measure which assesses sleep quality and disturbances in the last 2 weeks prior to the visit. Change from baseline PSQI score after both 9 to 39 days (follow-up 1) and approx. 3.5 months (follow-up 2).
Secondary Global Assessment of Functioning (GAF) A numeric scale used by the investigators to rate the current social, occupational, and psychological functioning of a participants. Scores range from 100 (extremely high functioning) to 1 (severely impaired). Change from screening GAF score after both 10 to 50 days (follow-up 1) and approx. 4 months (follow-up 2).
Secondary Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) A 30-item structured interview that is used to assess the 20 DSM-5 PTSD symptoms, subjective distress, impact of symptoms on social and occupational functioning, improvement in symptoms since the previous CAPS administration, and overall PTSD severity, and specifications for the dissociative subtype. Change from screening CAPS-5 score after approx. 4 months (follow-up 2).
Secondary Changes in the Interview for Psychotropic Drug Consumption (IPDC) A structured interview assessing self-reported patterns of use of common licit and illicit substances during the most representative month of the past year and, in the case of regular cocaine use, also specifically during the past month. Change from screening IPDC after approx. 4 months (follow-up 2).
See also
  Status Clinical Trial Phase
Recruiting NCT04317820 - Deep Brain Reorienting in Post-traumatic Stress Disorder N/A
Completed NCT05112003 - Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot N/A
Recruiting NCT04518267 - Anger and Psychotrauma: Data From Military and Civilians
Completed NCT02502604 - Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder N/A
Terminated NCT02234687 - A mGlu2/3 Agonist in the Treatment of PTSD Phase 1
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Completed NCT01738308 - The Effects of Healing Touch on Post Operative Pediatric Patients N/A
Terminated NCT02520726 - PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims Phase 4
Completed NCT02213900 - Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy Phase 4
Completed NCT01517711 - Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Phase 4
Completed NCT01437891 - Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF) N/A
Completed NCT01199107 - Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD) Phase 3
Completed NCT01998100 - Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD) Phase 3
Completed NCT01231711 - Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention Phase 1
Completed NCT00348036 - Group Intervention for Interpersonal Trauma N/A
Completed NCT00838006 - Psychophysiologic Predictors of Post-deployment Mental Health Outcomes N/A
Completed NCT00680524 - Telephone-based Care for OEF/OIF Veterans With PTSD N/A
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00158262 - Effect of Propranolol on Preventing Posttraumatic Stress Disorder Phase 4
Completed NCT00183690 - Prolonged Exposure Therapy Versus Active Psychotherapy in Treating Post-Traumatic Stress Disorder in Adolescents Phase 1